Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022 Jul 27;14:499-511. doi: 10.2147/CEOR.S359025
Williamson DB, Haltiwanger RS. Identification, function, and biological relevance of POGLUT2 and POGLUT3. Biochem Soc Trans. 2022 Apr 29;50(2):1003-12. doi: 10.1042/BST20210850
Mareque M, Montesinos P, Font P, Guinea JM, de la Fuente A, Soto J, Oyaguez I, Brockbank J, Iglesias T, Llinares J, Sierra J. Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with Cd-33 positive acute myeloid leukaemia in Spain. Clinicoecon Outcomes Res. 2021 Apr 22;2021(13):263-77. doi: 10.2147/CEOR.S302097
Sansom SL, Hicks KA, Carrico J, Jacobson EU, Shrestha RK, Green TA, Purcell DW. Optimal allocation of societal HIV prevention resources to reduce HIV incidence in the United States. Am J Public Health. 2021 Jan;111(1):150-8. doi: 10.2105/AJPH.2020.305965
Mladsi D, Barnett C, Aggarwal K, Vredenburg M, Dieterich D, Kim R. Cost-effectiveness of avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Clinicoecon Outcomes Res. 2020 Sep 14;2020(12):515-26. doi: 10.2147/CEOR.S262772
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Rajagopalan K, Candrilli SD, Ajmera M. Impact of antiepileptic drug-treatment burden on health-care-resource utilization and costs. Clinicoecon Outcomes Res. 2018 Oct 16;2018(10):619-27. doi: 10.2147/CEOR.S180913
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Mao N, Lesher B, Liu Q, Qin L, Chen Y, Gao X, Earnshaw SR, McDade CL, Claudie C. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China. Clinicoecon Outcomes Res. 2016 Jun;8:275-85.
Lupo PJ, Danysh HE, Symanski E, Langlois PH, Cai Y, Swartz MD. Neighborhood-based socioeconomic position and risk of oral clefts among offspring. Am J Public Health. 2015 Dec;105(12):2518-25. doi: 10.2105/AJPH.2015.302804
Spinner DS, Birt J, Walter JW, Bowman L, Mauskopf J, Drummond MF, Copley-Merriman C. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions. Clinicoecon Outcomes Res. 2013 Jan 1;5:69-85.
Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005 Jan 1;95(Suppl 1):S144-150.
Bauman KE, Foshee VA, Ennett ST, Pemberton M, Hicks KA, King TS, Koch GG. The influence of a family program on adolescent tobacco and alcohol use. Am J Public Health. 2001 Apr 1;91(4):604-10.
Rothman KJ, Cann CI, Fried MP. Carcinogenicity of dark liquor. Am J Public Health. 1989 Nov;79(11):1516-20.
Flanders WD, Rothman KJ. Occupational risk for laryngeal cancer. Am J Public Health. 1982 Apr 1;72(4):369-72.
Walker AM, Dreyer NA, Friedlander E, Loughlin JE, Rothman KJ, Kohn HI. An independent analysis of the National Cancer Institute study of non-nutritive sweeteners and bladder cancer. Am J Public Health. 1982 Apr;72(4):376-81.
Mackay AM, Rothman KJ. The incidence and severity of burn injuries following Project Burn Prevention. Am J Public Health. 1982 Mar;72(3):248-52.
Jick H, Walker AM, Rothman KJ. The epidemic of endometrial cancer: a commentary. Am J Public Health. 1980 Mar;70(3):264-7.